XML 52 R32.htm IDEA: XBRL DOCUMENT v3.24.0.1

Related Parties Transactions (Tables)

9 Months Ended

12 Months Ended

Sep. 30, 2023

Dec. 31, 2022

Related Parties Transactions [Abstract]

Schedule of Related Parties of the Company with whom Transactions

The related parties of the company with whom transactions are reported in these financial statements are as follows:

Name of entity or Individual		Relationship with the Company and its subsidiaries
BioFirst Corporation (the “BioFirst”)		Entity controlled by controlling beneficiary shareholder of YuanGene
BioFirst (Australia) Pty Ltd. (the “BioFirst (Australia)”)		100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene
Rgene Corporation (the “Rgene”)		Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene; the Chairman of Rgene is Mr. Tsung-Shann Jiang
YuanGene Corporation (the “YuanGene”)		Controlling beneficiary shareholder of the Company
AsiaGene Corporation (the “AsiaGene”)		Shareholder; entity controlled by controlling beneficiary shareholder of YuanGene
Eugene Jiang		Former President and Chairman
Keypoint Technology Ltd. (the “Keypoint’)		The Chairman of Keypoint is Eugene Jiang’s mother.
Lion Arts Promotion Inc. (the “Lion Arts”)		Shareholder of the Company
Yoshinobu Odaira (the “Odaira”)		Director of the Company
GenePharm Inc. (the “GenePharm”)		Dr. George Lee, Board Director of BioKey, is the Chairman of GenePharm.
Euro-Asia Investment & Finance Corp Ltd. (the “Euro-Asia”)		Shareholder of the Company
LBG USA, Inc. (the “LBG USA”)		100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene
LionGene Corporation (the “LionGene”)		Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene
Kimho Consultants Co., Ltd. (the “Kimho”)		Shareholder of the Company
The Jiangs		Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company; the Chairman of Rgene; the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang’s wife, is the Chairman of Keypoint; and a member of board of directors of BioLite Inc. Mr. Eugene Jiang is Mr. and Ms. Jiang’s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc. Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang’s sibling and the director of the Company. Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang’s sibling.
Amkey Ventures, LLC (“Amkey”)		An entity controlled by Dr. George Lee, who serves as one of the board directors of BioKey, Inc
BioLite Japan		Entity controlled by controlling beneficiary shareholder of ABVC
BioHopeKing Corporation		Entity controlled by controlling beneficiary shareholder of ABVC
ABVC BioPharma (HK), Limited		An entity 100% owned by Mr. Tsung-Shann Jiang

The related parties of the company with whom transactions are reported in these financial statements are as follows:

Name of entity or Individual		Relationship with the Company and its subsidiaries
BioFirst Corporation (the “BioFirst”)		Entity controlled by controlling beneficiary shareholder of YuanGene
BioFirst (Australia) Pty Ltd. (the “BioFirst (Australia)”)		100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene
Rgene Corporation (the “Rgene”)		Shareholder of the Company; entity controlled by controlling beneficiary shareholder of YuanGene
YuanGene Corporation (the “YuanGene”)		Controlling beneficiary shareholder of the Company
AsiaGene Corporation (the “AsiaGene”)		Shareholder; entity controlled by controlling beneficiary shareholder of YuanGene
Eugene Jiang		Former President and Chairman
Keypoint Technology Ltd. (the “Keypoint’)		The Chairman of Keypoint is Eugene Jiang’s mother.
Lion Arts Promotion Inc. (the “Lion Arts”)		Shareholder of the Company
Yoshinobu Odaira (the “Odaira”)		Director of the Company
GenePharm Inc. (the “GenePharm”)		Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm.
Euro-Asia Investment & Finance Corp Ltd. (the “Euro-Asia”)		Shareholder of the Company
LBG USA, Inc. (the “LBG USA”)		100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene
LionGene Corporation (the “LionGene”)		Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene
Kimho Consultants Co., Ltd. (the “Kimho”)		Shareholder of the Company
The Jiangs		Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang’s wife, is the Chairman of Keypoint; and a member of board of directors of BioLite Inc. Mr. Eugene Jiang is Mr. and Ms. Jiang’s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc. Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang’s sibling and the director of the Company. Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang’s sibling.
Amkey Ventures, LLC (“Amkey”)		An entity controlled by Dr. George Lee, who serves as one of the board directors of BioKey, Inc
BioLite Japan		Entity controlled by controlling beneficiary shareholder of ABVC
BioHopeKing Corporation		Entity controlled by controlling beneficiary shareholder of ABVC
ABVC BioPharma (HK), Limited		An entity 100% owned by Mr. Tsung-Shann Jiang

Schedule of Accounts Receivable Due from Related Parties

Accounts receivable due from related parties consisted of the following as of the periods indicated:

		September 30,				December 31,
		2023				2022
		(Unaudited)
GenePharm Inc.		$	-			$	142,225
Rgene			624,373				615,118
Total		$	624,373			$	757,343

Accounts receivable due from related parties consisted of the following as of the periods indicated:

		December 31,				December 31,
		2022				2021
GenePharm Inc.		$	142,225			$	142,225
Rgene			615,118				2,374
Amkey			-				800
Total		$	757,343			$	145,399

Schedule of Revenue Due from Related Parties

Revenue due from related parties consisted of the following as of the periods indicated:

		September 30,				September 30,
		2023				2022
		(Unaudited)				(Unaudited)
Rgene		$	1,900			$	307,788
Total		$	1,900			$	307,788

Schedule of Due from Related Parties - Current

Due from related–party - Current

		September 30,				December 31,
		2023				2022
		(Unaudited)
Rgene		$	535,046			$	513,819
Total		$	535,046			$	513,819

Due from related party- Current

		December 31,				December 31,
		2022				2021
Rgene		$	513,819			$	-
Total		$	513,819			$	-

Schedule of Due from Related Parties - Non Current

Due from related parties – Non-Current

		September 30,				December 31,
		2023				2022
		(Unaudited)
BioFirst (Australia)		$	822,781			$	752,655
BioHopeKing Corporation			107,615				112,822
Total		$	930,396			$	865,477

Due from related parties- Noncurrent

		December 31,				December 31,
		2022				2021
Rgene		$	-			$	49,110
BioFirst (Australia)			1,028,556				491,816
BioHopeKing Corporation			112,822				124,972
LBG USA			-				675
BioLite Japan			-				150,000
Keypoint			-				1,610
Total		$	1,141,378			$	818,183

Schedule of Amount Due to Related Parties

Amount due to related parties consisted of the following as of the periods indicated:

		September 30,				December 31,
		2023				2022
		(Unaudited)
BioFirst Corporation		$	315,947			$	188,753
The Jiangs			19,789				19,789
Due to shareholders			144,460				151,450
Total		$	480,196			$	359,992

Amount due to related parties consisted of the following as of the periods indicated:

		December 31,				December 31,
		2022				2021
BioFirst Corporation		$	188,753			$	40,878
BioFirst (Australia)			275,901				132,443
AsiaGene			-				24,017
YuanGene			-				9,205
The Jiangs			19,789				18,750
Due to shareholders			151,450				168,131
Total		$	635,893			$	393,424

Schedule of Revenue from Related Party

Revenue from related party

		Year Ended December 31,
		2022				2021
Rgene		$	904,043			$	2,373
Total		$	904,043			$	2,373

X

- References

No definition available.

+ Details

Name:	abvc_ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock
Namespace Prefix:	abvc_
Data Type:	dtr:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of related party transactions. Amount due to related party.

+ References

No definition available.

+ Details

Name:	abvc_ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty
Namespace Prefix:	abvc_
Data Type:	dtr:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of information revenue due from related party.

+ References

No definition available.

+ Details

Name:	abvc_ScheduleOfRevenueDueFromRelatedPartyTextBlock
Namespace Prefix:	abvc_
Data Type:	dtr:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Schedule of Revenue from related party.

+ References

No definition available.

+ Details

Name:	abvc_ScheduleOfRevenueFromRelatedPartyTableTextBlock
Namespace Prefix:	abvc_
Data Type:	dtr:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RelatedPartyTransactionsAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.3,4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.

+ References

No definition available.

+ Details

Name:	us-gaap_ScheduleOfDebtTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.

+ References

No definition available.

+ Details

Name:	us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration